Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Struggling to keep your New Year's resolutions? Here's how to keep yourself on track - 2At least 490 protesters killed in Iran, activists say
- 3Which Film Has the Incomparable Melodic Score?
- 4Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- 5Finding Your Motivation: Moves toward a Satisfying Life
- HGV driver recruited others to smuggle migrants
- Artemis will take Americans to the moon for the 1st time since 1972. Why has it been so hard to go back?
- Supercharge Your Remote Work Arrangement with These Game-Changing Instruments
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- Instructions to Expand Your Advantages from an Open Record Reward
- Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
- Antimatter took to the road for the very first time. Here’s why it matters
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- Kaiser Permanente affiliates to pay $556 million to resolve US claims alleging Medicare fraud
